In addition, analysis of myeloid subtypes in CT26 tumors from ceralasertib treated mice also showed a significant decrease in the number of tumor associated macrophages and increased percentage of CD11c+MHC II+ DCs (Supplementary Fig. 8E). Here, ITGAX is linked to neoplasm.